{"id":"pyrrotini","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Tianjin Medical University Cancer Institute and Hospital","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["CAPECITABINE"],"company":"Tianjin Medical University Cancer Institute and Hospital","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PYRROTINI","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:06:13.960885+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:06:21.709968+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PYRROTINI","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:06:21.999038+00:00"}},"allNames":["pyrrotini"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Pyrrotini's mechanism of action is likely to involve the inhibition of a specific enzyme or receptor, which plays a critical role in the regulation of cell growth and survival. Further research is needed to identify the exact target and mechanism of action of this drug."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pyrrotini","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pyrrotini","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:25:35.064114","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:06:24.315253+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"pyrrotini","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04767828","phase":"PHASE4","title":"A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-05-01","conditions":["TTP"],"enrollment":43,"completionDate":"2022-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Tianjin Medical University Cancer Institute and Hospital","relationship":"Original Developer"}],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Tianjin Medical University Cancer Institute and Hospital","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"PYRROTINI","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:06:24.315253+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}